Butikofer L, Varisco PA, Distler O, Kowal-Bielecka O, Allanore Y, Riemekasten G, et al. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. Arthritis Res Ther 2020;22(1):59. https://www.ncbi.nlm.nih.gov/pubmed/32209135
Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;8(10):963-74. https://www.ncbi.nlm.nih.gov/pubmed/32866440
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases 2017;76(8):1327-39. https://www.ncbi.nlm.nih.gov/pubmed/27941129
Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012;39(6):1241-7. https://www.ncbi.nlm.nih.gov/pubmed/22467932
Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44(6):1351-8. https://www.ncbi.nlm.nih.gov/pubmed/11407694
Roofeh D, Jaafar S, Vummidi D, Khanna D. Management of systemic sclerosis-associated interstitial lung disease. Curr Opin Rheumatol 2019;31(3):241-9. https://www.ncbi.nlm.nih.gov/pubmed/30870216
Roofeh D, Lescoat A, Khanna D. Treatment for systemic sclerosis-associated interstitial lung disease. Curr Opin Rheumatol 2021;33(3):240-8. https://www.ncbi.nlm.nih.gov/pubmed/33741803
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine 2018;378(1):35-47. https://www.ncbi.nlm.nih.gov/pubmed/29298160
van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35(4):364-72. https://www.ncbi.nlm.nih.gov/pubmed/8624641
Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005;52(9):2873-81. https://www.ncbi.nlm.nih.gov/pubmed/16142730
